Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 0.06%.

  • Keros Therapeutics' Return on Capital Employed rose 4800.0% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 4800.0%. This contributed to the annual value of 0.45% for FY2024, which is 900.0% up from last year.
  • Per Keros Therapeutics' latest filing, its Return on Capital Employed stood at 0.06% for Q3 2025, which was up 4800.0% from 0.0% recorded in Q2 2025.
  • Keros Therapeutics' Return on Capital Employed's 5-year high stood at 0.06% during Q3 2025, with a 5-year trough of 0.52% in Q4 2023.
  • In the last 5 years, Keros Therapeutics' Return on Capital Employed had a median value of 0.37% in 2022 and averaged 0.31%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -1900bps in 2022, then skyrocketed by 4800bps in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' Return on Capital Employed stood at 0.24% in 2021, then tumbled by -79bps to 0.44% in 2022, then decreased by -20bps to 0.52% in 2023, then increased by 30bps to 0.37% in 2024, then skyrocketed by 116bps to 0.06% in 2025.
  • Its Return on Capital Employed stands at 0.06% for Q3 2025, versus 0.0% for Q2 2025 and 0.02% for Q1 2025.